SOHO 2023 Eleventh Annual Meeting

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

SOHO 2023 Eleventh Annual Meeting

Leukemia
Lymphoma
Myeloma
MDS and MPN
Videos

Playback speed

10 seconds

SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment in Frontline CLL?

By SOHO 2023 Eleventh Annual Meeting FEATURING Alessandra Ferrajoli

0 views

October 6, 2023

Comments 0

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Leukemia

37:10

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML and Pregnancy

Feat. E. Abruzzese

11:02

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: AML

Feat. F. Ravandi

57:31

SOHO 2023 Eleventh Annual Meeting

Personalized Care for CLL/SLL: Achieving Better Total Care With Targ…

Feat. W. Wierda, N. Lamanna, M. Thompson

10:22

SOHO 2023 Eleventh Annual Meeting

CLL: Next Questions

Feat. N. Jain

10:37

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CML

Feat. P. Rousselot

10:16

SOHO 2023 Eleventh Annual Meeting

Next Questions in ALL

Feat. E. Jabbour

13:18

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the WHO Classification of AML?

Feat. S. Loghavi

15:12

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the ICC Classification of AML?

Feat. R. Hasserjian

10:22

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Do We Reconcile These AML Classifications in Clinical…

Feat. A. Wei

16:55

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Post-Transplant Maintenance Therapy for Patients With AML:…

Feat. B. Oran

15:27

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Prior Therapy Not Needed for Transplanting Patient…

Feat. J. Schetelig

12:17

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Achieving Best Response Is Desirable Prior to Allo…

Feat. R. Walter

16:11

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Familial Predisposition to AML: Prevalence & Implicati…

Feat. L. Godley

08:22

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Impact of Consolidation Chemo Intensity Before Allogeneic…

Feat. Y. Hicheri

15:01

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Patients With AML and Active Disease Should Be Tra…

Feat. H. Fernandez

13:59

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Against Allogeneic Transplantation for AML Patient…

Feat. E. Waller

12:48

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Genomic Complexity Beyond BCR::ABL1 and Its Clinical Impa…

Feat. D. Ross

13:31

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Epigenetic Dysregulation of CML

Feat. T. Ong

16:25

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross

07:50

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Phase II PACE Trial 5-Year Data: Early Cytogenetic or Mole…

Feat. H. Kantarjian

15:49

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Thera…

Feat. T. Munir

16:22

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Clinical Significance of MBL

Feat. S. Parikh

15:57

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Future of Menin Inhibitors in AML?

Feat. G. Issa

15:40

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CNS Prophylaxis in ALL

Feat. P. Kebriaei

09:01

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Sequencing Immunotherapies in Adults With B-ALL

Feat. B. Shah

15:23

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

Feat. J. Park

07:04

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Comparison of Treatment Outcomes in Adolescents and Young…

Feat. O. Shahin

08:21

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Results from the QuANTUM-First Trial: Impact of allo-HCT i…

Feat. A. Perl

13:39

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo

23:11

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Navigating the Treatment Value of TKIs in CML in the Era …

Feat. H. Kantarjian

08:35

SOHO 2023 Eleventh Annual Meeting

Liso-Cel in R/R CLL/SLL: Primary Analysis of the Phase 1/2, Single-A…

Feat. T. Siddiqi

17:30

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger

17:27

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How We Developed a Curative Therapy for CLL and Stopped U…

Feat. J. Seymour

16:04

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment …

Feat. A. Ferrajoli

26:59

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Debate: MRD+ After 1 Year of VenG in CLL - Stop or Continu…

Feat. O. Al-Sawaf, N. Lamanna

19:15

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés

20:29

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Slow-Motion Therapeutic Revolution in Adult ALL

Feat. H. Kantarjian

15:34

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is AML With Monocytic Features a Separate Entity?

Feat. D. Pollyea

18:13

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Role of Quizartinib in the Current Landscape …

Feat. H. Erba

08:22

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 First Report of Phase 3 PhALLCON Study: Comparing Ponatini…

Feat. E. Jabbour

17:45

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Acute Leukemia of Ambiguous Lineage

Feat. C. Saygin

15:25

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Management of Newly Diagnosed Ph+ ALL: Novel Drugs and Str…

Feat. E. Jabbour

13:15

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

Feat. E. Stein

15:42

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Approach to Ph-Like ALL

Feat. I. Iacobucci